Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botulinum Toxin B for Hidradenitis Suppurativa
NCT03103074Phase 2Completed
- Sponsor
- University Hospital of North Norway
- Start
- Jun 2017
- Primary completion
- Mar 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in hidradenitis suppurativa (HS) comparing Botulinum B Toxin with Placebo (2 arms). Primary endpoint: Patient reported improvement after intervention with Botulinum toxin B at 6 months. Started Jun 2017; status: completed.
02
Drugs
botulinum toxin type b
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NCT03103074.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03103074.